You are here

  • Home
  • Archive
  • Volume 12, Issue 3
  • Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors

Article info

Article menu
Oncolytic and local immunotherapy
Original research
Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors

Authors

  • Sara Feola University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, FinlandHelsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, FinlandTranslational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, FinlandDigital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Firas Hamdan University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, FinlandHelsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, FinlandTranslational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, FinlandDigital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Salvatore Russo University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, FinlandHelsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, FinlandTranslational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, FinlandDigital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Jacopo Chiaro University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, FinlandHelsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, FinlandTranslational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, FinlandDigital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Manlio Fusciello University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, FinlandHelsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, FinlandTranslational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, FinlandDigital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Michaela Feodoroff University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, FinlandHelsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, FinlandTranslational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, FinlandDigital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Gabriella Antignani University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, FinlandHelsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, FinlandTranslational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, FinlandDigital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Federica D'Alessio University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, FinlandHelsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, FinlandTranslational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, FinlandDigital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Riikka Mölsä University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, FinlandHelsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, FinlandTranslational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, FinlandDigital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Virpi Stigzelius University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, FinlandHelsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, FinlandTranslational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, FinlandDigital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Paolo Bottega University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, FinlandHelsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, FinlandTranslational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, FinlandDigital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Sari Pesonen Valo Therapeutics Oy, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Jeanette Leusen Center for translational immunology, UMC Utrecht, Utrecht, The Netherlands PubMed articlesGoogle scholar articles
  • Mikaela Grönholm University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, FinlandHelsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, FinlandTranslational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, FinlandDigital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland PubMed articlesGoogle scholar articles
  • Vincenzo Cerullo University of Helsinki Faculty of Pharmacy, Laboratory of Immunovirotherapy, Drug Research Program Helsinki, Uusimaa, FI, Helsinki, FinlandHelsinki Institute of Life Science (HiLIFE), Fabianinkatu 33, University of Helsinki, 00710 Helsinki, Finland, Helsinki, FinlandTranslational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, Helsinki, FinlandDigital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, FinlandDepartment of Molecular Medicine and Medical Biotechnology and CEINGE, Naples University Federico II, Naples, Italy PubMed articlesGoogle scholar articles

Citation

Feola S, Hamdan F, Russo S, et al
Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors
Journal for ImmunoTherapy of Cancer 2024;12:e008342. doi: 10.1136/jitc-2023-008342
Online issue publication 
March 08, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.